Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue (2020 - 2022)

Xeris Biopharma Holdings (XERS) has 3 years of Non-Current Deffered Revenue data on file, last reported at $6.6 million in Q3 2022.

• Quarterly Non-Current Deffered Revenue fell 2.65% year-over-year to $6.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $6.6 million (down 2.65% YoY) and the FY2021 annual result came in at $6.9 million, up 3.83% from the prior year.
• Non-Current Deffered Revenue declined to $6.6 million in Q3 2022, from $6.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $6.9 million in Q1 2022 to a low of $6.6 million in Q4 2020.
• A 3-year average of $6.8 million and a median of $6.8 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue gained 3.83% — and 2022, when it fell 2.65%.
• Tracing XERS's Non-Current Deffered Revenue over 3 years: stood at $6.6 million in 2020, then grew by 3.83% to $6.9 million in 2021, then retreated by 3.46% to $6.6 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $6.6 million (Q3 2022), $6.8 million (Q2 2022), and $6.9 million (Q1 2022), per Business Quant data.